Liver X receptor agonists have been combined with other antitumor agents with promising activity in preclinical studies of melanoma (vemurafenib, dacarbazine [DTIC], anti‐CTLA‐4 antibody) and pancreatic cancer (gemcitabine) [24, 44]. The gene discussed is CTLA4; the disease is melanoma.